Dataset from Phase 2, Open-label, Multiple-dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Delamanid (OPC-67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs Over a 6-Month Treatment Period
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00008981
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this trial is to assess the safety, tolerability, pharmacokinetics, and
efficacy of long-term (6-month) treatment with delamanid plus an optimized background regimen
(OBR) of other anti-tuberculosis drugs in pediatric participants who completed Study
242-12-232 (NCT01856634).
创建时间：
2024-11-26
